{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:50:44Z","timestamp":1787691044623,"version":"build-2784847793"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00403-015-1571-1","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T04:56:03Z","timestamp":1431924963000},"page":"767-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the \u2018future\u2019 in dermatology therapeutics?"],"prefix":"10.1007","volume":"307","author":[{"given":"Mrinal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram K.","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karaninder S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpinder S.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,19]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11926-007-0008-z","volume":"9","author":"DJ Abraham","year":"2007","unstructured":"Abraham DJ, Eckes B, Rajkumar V, Krieg T (2007) New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9:136\u2013143","journal-title":"Curr Rheumatol Rep"},{"key":"1571_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ced.12394","volume":"39","author":"K Amr","year":"2014","unstructured":"Amr K, Abdel-Hameed M, Sayed K, Nour-Edin F, Abdel Hay R (2014) The Pro12Ala polymorphism of the gene for peroxisome proliferator-activated receptor gamma is associated with a lower Global Acne Grading System score in patiemts with acne vulgaris. Clin Exp Dermatol 39:741\u2013745","journal-title":"Clin Exp Dermatol"},{"key":"1571_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","volume":"133","author":"E Arioglu","year":"2000","unstructured":"Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J et al (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133:263\u2013274","journal-title":"Ann Intern Med"},{"key":"1571_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archdermatol.2007.22","volume":"144","author":"R Behshad","year":"2008","unstructured":"Behshad R, Cooper KD, Korman NJ (2008) A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 144:84\u201388","journal-title":"Arch Dermatol"},{"key":"1571_CR5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/keh423","volume":"44","author":"T Bongartz","year":"2005","unstructured":"Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U (2005) Treatment of active psoriatic arthritis with the PPAR\u03b3 ligand pioglitazone: an open-label pilot study. Rheumatology 44:126\u2013129","journal-title":"Rheumatology"},{"key":"1571_CR6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/jid.2008.346","volume":"129","author":"T Botton","year":"2009","unstructured":"Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP et al (2009) In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol 129:1208\u20131212","journal-title":"J Invest Dermatol"},{"key":"1571_CR7","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1210\/endo.139.6.6049","volume":"139","author":"O Braissant","year":"1998","unstructured":"Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-activated receptor-alpha-beta, and -gamma during rat embryonic development. Endocrinology 139:2748\u20132754","journal-title":"Endocrinology"},{"key":"1571_CR8","doi-asserted-by":"crossref","first-page":"L1146","DOI":"10.1152\/ajplung.00383.2004","volume":"288","author":"HA Burgess","year":"2005","unstructured":"Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnnet M et al (2005) PPAR gamma agonists inhibit TGF-beta induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288:L1146\u2013L1153","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1571_CR9","doi-asserted-by":"crossref","first-page":"507141","DOI":"10.1155\/2009\/507141","volume":"2009","author":"M Caron","year":"2009","unstructured":"Caron M, Vigouroux C, Bastard J-P, Capeau J (2009) Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPAR\u03b3-dependent pathways. PPAR Res 2009:507141. doi: 10.1155\/2009\/507141","journal-title":"PPAR Res"},{"key":"1571_CR10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","volume":"363","author":"A Carr","year":"2004","unstructured":"Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D et al (2004) No effect of Rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429\u2013438","journal-title":"Lancet"},{"key":"1571_CR11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/518005","volume":"195","author":"RB Cavalcanti","year":"2007","unstructured":"Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S (2007) A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 195:1754\u20131761","journal-title":"J Infect Dis"},{"key":"1571_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1523-1747.2003.12411.x","volume":"121","author":"W Chen","year":"2003","unstructured":"Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis CC (2003) Expression of peroxisome proliferator-activated receptor and CCAAT\/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 121:441\u2013447","journal-title":"J Invest Dermatol"},{"key":"1571_CR13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1398-9995.2012.02844.x","volume":"67","author":"T Chiba","year":"2012","unstructured":"Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara K, Moroi Y et al (2012) Topical application of PPAR alpha (but not beta\/delta or gamma) suppresses atopic dermatitis in NC\/Nga mice. Allergy 67:936\u2013942","journal-title":"Allergy"},{"key":"1571_CR14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1189\/jlb.71.3.388","volume":"71","author":"RB Clark","year":"2002","unstructured":"Clark RB (2002) The role of PPARs in inflammation and immunity. J Leukoc Bio 71:388\u2013400","journal-title":"J Leukoc Bio"},{"key":"1571_CR15","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/archderm.140.12.1504","volume":"140","author":"B Coras","year":"2004","unstructured":"Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M et al (2004) Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic Kaposi sarcoma. Arch Dermatol 140:1504\u20131507","journal-title":"Arch Dermatol"},{"key":"1571_CR16","unstructured":"Critical therapeutics announces results from phase II study of Zileuton in acne patients. http:\/\/www.businesswire.com\/news\/home\/20050714005349\/en\/Critical-Therapeutics-Announces-Results-Phase-II-Study#.VLZ9DiuUdR4 . Accessed 20 Nov 2014"},{"key":"1571_CR17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2007.01444.x","volume":"62","author":"MS Dahten","year":"2007","unstructured":"Dahten MS, Worm M (2007) PPAR gamma expression profile and its cytokine driven regulation in atopic dermatitis. Allergy 62:926\u2013933","journal-title":"Allergy"},{"key":"1571_CR18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1600-0625.2009.00841.x","volume":"18","author":"M Demerjian","year":"2009","unstructured":"Demerjian M, Choi EH, Man S, Chang S, Elias PM, Feingold KR (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643\u2013649","journal-title":"Exp Dermatol"},{"key":"1571_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj.52.299","volume":"52","author":"D Dereli","year":"2005","unstructured":"Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C (2005) Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 52:299\u2013308","journal-title":"Endocr J"},{"key":"1571_CR20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s11745-004-1335-y","volume":"39","author":"N Di-Poi","year":"2004","unstructured":"Di-Poi N, Michalik L, Desvergne B, Wahli W (2004) Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids 39:1093\u20131099","journal-title":"Lipids"},{"key":"1571_CR21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/MCB.25.5.1696-1712.2005","volume":"25","author":"N Di-Poi","year":"2005","unstructured":"Di-Poi N, Ng CY, Tan NS, Yang Z, Hemmings BA, Desvergne B et al (2005) Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor \u03b2\/\u03b4 during hair follicle development. Mol Cell Biol 25:1696\u20131712","journal-title":"Mol Cell Biol"},{"key":"1571_CR22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1525-1470.2009.01042.x","volume":"26","author":"LF Eichenfield","year":"2009","unstructured":"Eichenfield LF, McCollum A, Msika P (2009) The benefits of sunflower oleodistillate (SOD) in pediatric dermatology. Pediatr Dermatol 26:669\u2013675","journal-title":"Pediatr Dermatol"},{"key":"1571_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/bbrc.1996.1044","volume":"224","author":"A Elbrecht","year":"1996","unstructured":"Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE et al (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 224:431\u2013437","journal-title":"Biochem Biophys Res Commun"},{"key":"1571_CR24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.136.5.609","volume":"136","author":"CN Ellis","year":"2000","unstructured":"Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC et al (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136:609\u2013616","journal-title":"Arch Dermatol"},{"key":"1571_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1684\/ejd.2011.1575","volume":"22","author":"NN Elmongy","year":"2012","unstructured":"Elmongy NN, Shaker O (2012) Expression of peroxisome proliferator activator receptor \u03b2\/\u03b4 in acne vulgaris. Eur J Dermatol 22:42\u201345","journal-title":"Eur J Dermatol"},{"key":"1571_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00001813-200603000-00011","volume":"17","author":"C Freudlsperger","year":"2006","unstructured":"Freudlsperger C, Moll I, Schumacher U, Thies A (2006) Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17:325\u2013332","journal-title":"Anticancer Drugs"},{"key":"1571_CR27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/00015550510030104","volume":"85","author":"PS Friedmann","year":"2005","unstructured":"Friedmann PS, Cooper HL, Healy E (2005) Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol 85:194\u2013202","journal-title":"Acta Derm Venereol"},{"key":"1571_CR28","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X","volume":"21","author":"P Gosset","year":"2001","unstructured":"Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J et al (2001) Peroxisome proliferator activated receptor gamma activators affect the maturation of human monocyte derived dendritic cells. Eur J Immunol 21:2857\u20132862","journal-title":"Eur J Immunol"},{"key":"1571_CR29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00403-004-0479-y","volume":"296","author":"M Grabacka","year":"2004","unstructured":"Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, Slominski A (2004) Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 296:54\u201358","journal-title":"Arch Dermatol Res"},{"key":"1571_CR30","doi-asserted-by":"crossref","first-page":"e37097","DOI":"10.1371\/journal.pone.0037097","volume":"7","author":"K Hack","year":"2012","unstructured":"Hack K, Reilly L, Palmer C, Read KD, Norval S, Kime R et al (2012) Skin targeted inhibition of PPAR \u03b2\/\u03b4 by selective antagonists to treat PPAR \u03b2\/\u03b4 mediated psoriasis-like skin disease. PLoS One 7:e37097","journal-title":"PLoS One"},{"key":"1571_CR31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","volume":"140","author":"C Hadigan","year":"2004","unstructured":"Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S (2004) Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 140:786\u2013794","journal-title":"Ann Intern Med"},{"key":"1571_CR32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1523-1747.1999.00743.x","volume":"113","author":"K Hanley","year":"1999","unstructured":"Hanley K, K\u00f6m\u00fcves LG, Bass NM, He SS, Jiang Y, Crumrine D et al (1999) Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 113:788\u2013795","journal-title":"J Invest Dermatol"},{"key":"1571_CR33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I","volume":"31","author":"SG Harris","year":"2001","unstructured":"Harris SG, Phipps RP (2001) The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 31:1098\u20131105","journal-title":"Eur J Immunol"},{"key":"1571_CR34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2009.06.049","volume":"125","author":"Y Hatano","year":"2010","unstructured":"Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Elias PM et al (2010) Murine atopic dermatitis responds to peroxisome proliferator activated receptor \u03b1, \u03b2\/\u03b4 (but not \u03b3), and liver-X-receptor activators. J Allergy Clin Immunol 125:160\u2013169","journal-title":"J Allergy Clin Immunol"},{"key":"1571_CR35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.jidsymp.5650007","volume":"11","author":"G Icre","year":"2006","unstructured":"Icre G, Wahli W, Michalik L (2006) Functions of the peroxisome proliferator-activated receptor (PPAR) \u03b1 and \u03b2 in skin homeostasis, epithelial repair, and morphogenesis. J Investig Dermatol Symp Proc 11:30\u201335","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1571_CR36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645\u2013650","journal-title":"Nature"},{"key":"1571_CR37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/0253-7613.27020","volume":"38","author":"VA Javiya","year":"2006","unstructured":"Javiya VA, Patel JA (2006) The role of peroxisome-proliferator activated receptors in human disease. Indian J Pharmacol 38:243\u2013253. doi: 10.4103\/0253-7613.27020","journal-title":"Indian J Pharmacol"},{"key":"1571_CR38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2567.2010.03261.x","volume":"130","author":"S Kanakasabai","year":"2010","unstructured":"Kanakasabai S, Cherwae W, Walline CC, Iams W, Adams SM, Bright JJ (2010) Peroxisome proliferator-activated receptor \u03b4 agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130:572\u2013588","journal-title":"Immunology"},{"key":"1571_CR39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2133.2004.05844.x","volume":"150","author":"HY Kang","year":"2004","unstructured":"Kang HY, Chung E, Lee M, Cho Y, Kang WH (2004) Expression and function of peroxisome proliferator-activated receptors in human melanocytes. Br J Dermatol 150:462\u2013468","journal-title":"Br J Dermatol"},{"key":"1571_CR40","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/art.24761","volume":"60","author":"M Kapoor","year":"2009","unstructured":"Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ et al (2009) Loss of PPAR\u03b3 in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 60:2822\u20132829","journal-title":"Arthritis Rheum"},{"key":"1571_CR41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/jid.2008.369","volume":"129","author":"P Karnik","year":"2009","unstructured":"Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD et al (2009) Hair follicle stem cell-specific PPAR-gamma deletion causes scarring alopecia. J Invest Dermatol 129:1243\u20131257","journal-title":"J Invest Dermatol"},{"key":"1571_CR42","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1084\/jem.20082771","volume":"206","author":"L Klotz","year":"2009","unstructured":"Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S et al (2009) The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 206:2079\u20132089","journal-title":"J Exp Med"},{"key":"1571_CR43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1523-1747.1998.00296.x","volume":"111","author":"LG K\u00f6m\u00fcves","year":"1998","unstructured":"K\u00f6m\u00fcves LG, Hanley K, Jiang Y, Elias PM, Willium ML, Feingold KR (1998) Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J Invest Dermatol 111:429\u2013433","journal-title":"J Invest Dermatol"},{"key":"1571_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1523-1747.2000.00076.x","volume":"115","author":"LG K\u00f6m\u00fcves","year":"2000","unstructured":"K\u00f6m\u00fcves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR (2000) Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPAR alpha activators restores tissue homeostasis. J Invest Dermatol 115:361\u2013367","journal-title":"J Invest Dermatol"},{"key":"1571_CR45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2133.2003.05532.x","volume":"149","author":"S Kuenzli","year":"2003","unstructured":"Kuenzli S, Saurat JH (2003) Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 149:229\u2013236","journal-title":"Br J Dermatol"},{"key":"1571_CR46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000068897","volume":"206","author":"S Kuenzli","year":"2003","unstructured":"Kuenzli S, Saurat JH (2003) Effect of topical PPAR\u03b2\/\u03b4 and PPAR\u03b3 agonists on plaque psoriasis. A pilot study. Dermatology 206:252\u2013256","journal-title":"Dermatology"},{"key":"1571_CR47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ijd.12585","volume":"54","author":"V Lajevardi","year":"2015","unstructured":"Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M (2015) The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 54:95\u2013101","journal-title":"Int J Dermatol"},{"key":"1571_CR48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1385\/MO:23:3:393","volume":"23","author":"Y Liu","year":"2006","unstructured":"Liu Y, Meng Y, Li H, Li J, Fu J, Liu Y et al (2006) Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 23:393\u2013402","journal-title":"Med Oncol"},{"key":"1571_CR49","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1464-5491.2005.01757.x","volume":"22","author":"A Ludtke","year":"2005","unstructured":"Ludtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ et al (2005) Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 22:1611\u20131613","journal-title":"Diabet Med"},{"key":"1571_CR50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.jid.5701026","volume":"128","author":"MQ Man","year":"2008","unstructured":"Man MQ, Barish GD, Schmuth D, Crumrine Y, Barak S, Chang Y et al (2008) Deficiency of PPAR beta\/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol 128:370\u2013377","journal-title":"J Invest Dermatol"},{"key":"1571_CR51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7241\/ourd.20142.27","volume":"5","author":"D Mahgoub","year":"2014","unstructured":"Mahgoub D, El Tawdy AM, Metwally D, Manar A, Rashed L (2014) Estmation of peroxisome-proliferator-activated receptor \u03b3 gene expression in inflammatory skin diseases: atopic dermatitis and psoriasis. Our Dermatol Online 5:107\u2013112","journal-title":"Our Dermatol Online"},{"key":"1571_CR52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.0022-202X.2004.23235.x","volume":"123","author":"M Mao-Qiang","year":"2004","unstructured":"Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE et al (2004) Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123:305\u2013312","journal-title":"J Invest Dermatol"},{"key":"1571_CR53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.RES.0000014225.20727.8F","volume":"90","author":"N Marx","year":"2002","unstructured":"Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V et al (2002) PPAR activators as anti-inflammatory mediators in human T lymphocytes; implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703\u2013710","journal-title":"Circ Res"},{"key":"1571_CR54","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1158\/1078-0432.CCR-05-0087","volume":"11","author":"T Masuda","year":"2005","unstructured":"Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T et al (2005) Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 11:4012\u20134021","journal-title":"Clin Cancer Res"},{"key":"1571_CR55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1083\/jcb.200011148","volume":"154","author":"L Michalik","year":"2001","unstructured":"Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J et al (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta mutant mice. J Cell Biol 154:799\u2013814","journal-title":"J Cell Biol"},{"key":"1571_CR56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00424-009-0776-6","volume":"459","author":"JF Michiels","year":"2010","unstructured":"Michiels JF, Perrin C, Leccia N, Massi D, Grimaldi P, Wagner N (2010) PPAR\u03b2 activation inhibits melanoma cell proliferation involving repression of the Wilms\u2019 tumour suppressor WT1. Pflugers Arch 459:689\u2013703","journal-title":"Pflugers Arch"},{"key":"1571_CR57","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archdermatol.2009.283","volume":"145","author":"P Mirmirani","year":"2009","unstructured":"Mirmirani P, Karnik P (2009) Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol 145:1363\u20131366","journal-title":"Arch Dermatol"},{"key":"1571_CR58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1515\/bmc-2012-0035","volume":"4","author":"A Montagner","year":"2013","unstructured":"Montagner A, Wahli W (2013) Contributions of peroxisome proliferator-activated receptor \u03b2\/\u03b4 to skin health and disease. Biomol Concepts 4:53\u201364","journal-title":"Biomol Concepts"},{"key":"1571_CR59","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1523-1747.2002.01861.x","volume":"119","author":"R Mossner","year":"2002","unstructured":"Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L et al (2002) Agonists of peroxisome proliferator-activated receptor \u03b3 inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576\u2013582","journal-title":"J Invest Dermatol"},{"key":"1571_CR60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","volume":"21","author":"K Mulligan","year":"2007","unstructured":"Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL et al (2007) Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio. AIDS 21:47\u201357","journal-title":"AIDS"},{"key":"1571_CR61","author":"MD Neher","year":"2012","unstructured":"Neher MD, Weckbach S, Huber-Lang MS, Stahel PF (2012) New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res. doi: 10.1155\/2012\/728461","journal-title":"PPAR Res"},{"key":"1571_CR62","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.169.3.1228","volume":"169","author":"A Nencioni","year":"2002","unstructured":"Nencioni A, Grunebach F, Zobywlaski A, Denzlinger C, Brugger W, Brossart P (2002) Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 169:1228\u20131235","journal-title":"J Immunol"},{"key":"1571_CR63","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/carcin\/bgh160","volume":"25","author":"CJ Nicol","year":"2004","unstructured":"Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM et al (2004) PPAR{gamma} influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 25:1747\u20131755","journal-title":"Carcinogenesis"},{"key":"1571_CR64","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2133.2004.06214.x","volume":"151","author":"T Nijsten","year":"2004","unstructured":"Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 151:837\u2013845","journal-title":"Br J Dermatol"},{"key":"1571_CR65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.0303-6987.2005.00345.x","volume":"32","author":"T Nijsten","year":"2005","unstructured":"Nijsten T, Geluyckens E, Colpaert C, Lambert J (2005) Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 32:340\u2013347","journal-title":"J Cutan Pathol"},{"key":"1571_CR66","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1464-5491.2003.01034.x","volume":"20","author":"KR Owen","year":"2003","unstructured":"Owen KR, Donohoe M, Ellard S, Hattersley AT (2003) Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabetic Med 20:823\u2013827","journal-title":"Diabetic Med"},{"key":"1571_CR67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1517\/13543784.12.12.1925","volume":"12","author":"D Panigrahy","year":"2003","unstructured":"Panigrahy D, Shen LQ, Kieran MW, Kaipainen A (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12:1925\u20131937","journal-title":"Expert Opin Investig Drugs"},{"key":"1571_CR68","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","volume":"110","author":"D Panigrahy","year":"2002","unstructured":"Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ et al (2002) PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923\u2013932","journal-title":"J Clin Invest"},{"key":"1571_CR69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","volume":"101","author":"V Pasceri","year":"2000","unstructured":"Pasceri V, Wu HD, Willerson JT, Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:235\u2013238","journal-title":"Circulation"},{"key":"1571_CR70","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.134.10.1304","volume":"134","author":"HA Pershadsingh","year":"1998","unstructured":"Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM (1998) Treatment of psoriasis with troglitazone therapy. Arch Dermatol 134:1304\u20131305","journal-title":"Arch Dermatol"},{"key":"1571_CR71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008390-200310000-00003","volume":"13","author":"W Placha","year":"2003","unstructured":"Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003) The effect of PPAR gamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447\u2013456","journal-title":"Melanoma Res"},{"key":"1571_CR72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0625.2006.00504.x","volume":"16","author":"DA Plager","year":"2007","unstructured":"Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd et al (2007) Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 16:28\u201336","journal-title":"Exp Dermatol"},{"key":"1571_CR73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1310\/hct1101-39","volume":"11","author":"JM Raboud","year":"2010","unstructured":"Raboud JM, Dlong C, Carr A, Grinspoon S, Mulligan K, Sutinen J et al (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39\u201350","journal-title":"HIV Clin Trials"},{"key":"1571_CR74","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","volume":"1771","author":"M Ricote","year":"2007","unstructured":"Ricote M, Glass CK (2007) PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771:926\u2013935","journal-title":"Biochim Biophys Acta"},{"key":"1571_CR75","doi-asserted-by":"crossref","first-page":"e9701","DOI":"10.1371\/journal.pone.0009701","volume":"5","author":"M Romanowska","year":"2010","unstructured":"Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J (2010) Activation of PPAR \u03b2\/\u03b4 causes a psoriasis-like skin disease in vivo. PLoS One 5:e9701","journal-title":"PLoS One"},{"key":"1571_CR76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000017864","volume":"196","author":"RL Rosenfield","year":"1998","unstructured":"Rosenfield RL, Deplewski D, Kentsis A, Ciletti N (1998) Mechanisms of androgen induction of sebocyte differentiation. Dermatology 196:43\u201346","journal-title":"Dermatology"},{"key":"1571_CR77","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1046\/j.1523-1747.1999.00487.x","volume":"112","author":"RL Rosenfield","year":"1999","unstructured":"Rosenfield RL, Kentsis A, Deplewski D, Ciletti N (1999) Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 112:226\u2013232","journal-title":"J Invest Dermatol"},{"key":"1571_CR78","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1523-1747.2003.12493.x","volume":"121","author":"R R\u00fchl","year":"2003","unstructured":"R\u00fchl R, Dahten A, Schweigert FJ, Herz U, Worm M (2003) Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands. J Invet Dermatol 121:757\u2013764","journal-title":"J Invet Dermatol"},{"key":"1571_CR79","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-4632.2005.02504.x","volume":"44","author":"N Shafiq","year":"2005","unstructured":"Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K (2005) Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 44:328\u2013333","journal-title":"Int J Dermatol"},{"key":"1571_CR80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"JI Schamitt","year":"2008","unstructured":"Schamitt JI, Zhang Z, Wozel G, Meurer M, Kirch W (2008) Efficacy and tolerability of biologic and non-biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 159:513\u2013526","journal-title":"Br J Dermatol"},{"key":"1571_CR81","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.0022-202X.2004.22412.x","volume":"122","author":"M Schmuth","year":"2004","unstructured":"Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S et al (2004) Peroxisome proliferator-activated receptor (PPAR)-\u03b2\/\u03b4 Stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122:971\u2013983","journal-title":"J Invest Dermatol"},{"key":"1571_CR82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbalip.2013.11.012","volume":"1841","author":"M Schmuth","year":"2014","unstructured":"Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S (2014) Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta 1841:463\u2013473","journal-title":"Biochim Biophys Acta"},{"key":"1571_CR83","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1046\/j.1523-1747.2002.19605.x","volume":"119","author":"M Schmuth","year":"2002","unstructured":"Schmuth M, Schoonjans K, Yu QC, Fluhr JW, Crumrine D, Hachem JP et al (2002) Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J Invest Dermatol 119:1298\u20131303","journal-title":"J Invest Dermatol"},{"key":"1571_CR84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2133.2010.10037.x","volume":"164","author":"M Schuster","year":"2011","unstructured":"Schuster M, Zouboulis CC, Ochsendorf F, Muller J, Thaci D, Bernd A et al (2011) Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne? Br J Dermatol 164:182\u2013186","journal-title":"Br J Dermatol"},{"key":"1571_CR85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4161\/derm.15025","volume":"3","author":"P Sertznig","year":"2011","unstructured":"Sertznig P, Reichrath J (2011) Peroxisome proliferator-activated receptors (PPARs) in dermatology. Challenge and promise. Derm Endocrinol 3:130\u2013135","journal-title":"Derm Endocrinol"},{"key":"1571_CR86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00128071-200809010-00002","volume":"9","author":"P Sertznig","year":"2008","unstructured":"Sertznig P, Seifert M, Tilgen W, Reichrath J (2008) Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 9:15\u201331","journal-title":"Am J Clin Dermatol"},{"key":"1571_CR87","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1021\/bi00072a015","volume":"32","author":"T Sher","year":"1993","unstructured":"Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598\u20135604","journal-title":"Biochemistry"},{"key":"1571_CR88","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/rheumatology\/kep371","volume":"49","author":"X Shi-wen","year":"2010","unstructured":"Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ (2010) Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 49:259\u2013263","journal-title":"Rheumatology"},{"key":"1571_CR89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","volume":"13","author":"L Slama","year":"2008","unstructured":"Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A et al (2008) Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 13:67\u201376","journal-title":"Antivir Ther"},{"key":"1571_CR90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s102270000126","volume":"5","author":"KJ Smith","year":"2001","unstructured":"Smith KJ, Dipreta E, Skelton H (2001) Peroxisomes in dermatology. Part II. J Cutan Med Surg 5:315\u2013322","journal-title":"J Cutan Med Surg"},{"key":"1571_CR91","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaci.2007.12.1165","volume":"121","author":"D Staumont-Sall\u00e9","year":"2008","unstructured":"Staumont-Sall\u00e9 D, Abboud G, Br\u00e9nuchon C, Kanda A, Roumier T, Lavogiez C et al (2008) Peroxisome proliferatoractivated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962\u2013968","journal-title":"J Allergy Clin Immunol"},{"key":"1571_CR92","doi-asserted-by":"crossref","first-page":"373524","DOI":"10.1155\/2009\/373524","volume":"2009","author":"J Sutinen","year":"2009","unstructured":"Sutinen J (2009) The Effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res 2009:373524. doi: 10.1155\/2009\/373524","journal-title":"PPAR Res"},{"key":"1571_CR93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","volume":"8","author":"J Sutinen","year":"2003","unstructured":"Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Halavaara J, Jarvinen A et al (2003) Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 8:199\u2013207","journal-title":"Antivir Ther"},{"key":"1571_CR94","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1101\/gad.207501","volume":"15","author":"NS Tan","year":"2001","unstructured":"Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M et al (2001) Critical roles of PPAR beta\/delta in keratinocyte response to inflammation. Genes Dev 15:3263\u20133677","journal-title":"Genes Dev"},{"key":"1571_CR95","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4049\/jimmunol.164.2.1046","volume":"164","author":"R Thieringer","year":"2000","unstructured":"Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L et al (2000) Activation of peroxisome proliferator activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharides in vitro or in vivo. J Immunol 164:1046\u20131054","journal-title":"J Immunol"},{"key":"1571_CR96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F","volume":"29","author":"P Thuillier","year":"2000","unstructured":"Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ et al (2000) Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 29:134\u2013142","journal-title":"Mol Carcinog"},{"key":"1571_CR97","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-4632.2009.04105.x","volume":"48","author":"A Tirado-Sanchez","year":"2009","unstructured":"Tirado-Sanchez A, Santamaria-Roman A, Ponce-Olivera RM (2009) Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol 48:893\u2013895","journal-title":"Int J Dermatol"},{"issue":"126","key":"1571_CR98","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.jid.5700336","volume":"2006","author":"NR Trivedi","year":"2006","unstructured":"Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilla LL, Sivarajah S et al (2006) Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006(126):2002\u20132009","journal-title":"J Invest Dermatol"},{"key":"1571_CR99","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","volume":"2","author":"S Tyagi","year":"2011","unstructured":"Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2:236\u2013240","journal-title":"J Adv Pharm Technol Res"},{"key":"1571_CR100","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.11775","volume":"98","author":"T Vogt","year":"2003","unstructured":"Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A et al (2003) Antiangiogenic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251\u20132256","journal-title":"Cancer"},{"key":"1571_CR101","first-page":"83","volume":"132","author":"W Wahli","year":"2002","unstructured":"Wahli W (2002) Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 132:83\u201391","journal-title":"Swiss Med Wkly"},{"key":"1571_CR102","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1747.2001.01329.x","volume":"116","author":"M Westergaard","year":"2001","unstructured":"Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD et al (2001) Modulation of keratinocyte gene expression and differentiation by PPAR selective ligands and tetradecylthioacetic acid. J Invest Dermatol 116:702\u2013712","journal-title":"J Invest Dermatol"},{"key":"1571_CR103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1467-2494.2004.00256.x","volume":"27","author":"JW Wiechers","year":"2005","unstructured":"Wiechers JW, Rawlings AV, Garcia C, Chesne C, Balaguer P, Corre S et al (2005) A new mechanism of action for skin whitening agents: binding to the peroxisome proliferators-activated receptor. Int J Cosmet Sci 27:123\u2013132","journal-title":"Int J Cosmet Sci"},{"key":"1571_CR104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1523-1747.2003.12029.x","volume":"120","author":"A Wr\u00f3bel","year":"2003","unstructured":"Wr\u00f3bel A, Seltmann H, Fimmel S, M\u00fcller-Decker K, Tsukada M, Bogdanoff B et al (2003) Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol 120:175\u2013181","journal-title":"J Invest Dermatol"},{"key":"1571_CR105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator activated receptor-gamma. Am J Pathol 174:519\u2013533","journal-title":"Am J Pathol"},{"key":"1571_CR106","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1074\/jbc.274.13.9116","volume":"274","author":"X Xin","year":"1999","unstructured":"Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116\u20139121","journal-title":"J Biol Chem"},{"key":"1571_CR107","author":"Y Yang","year":"2010","unstructured":"Yang Y, Lovett-Racke AE, Racke MK (2010) Regulation of immune responses and autoimmune encephalomyelitis by PPARs. PPAR Res. doi: 10.1155\/2010\/104705","journal-title":"PPAR Res"},{"key":"1571_CR108","first-page":"w13071","volume":"140","author":"A Yessofou","year":"2010","unstructured":"Yessofou A, Wahli W (2010) Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 140:w13071","journal-title":"Swiss Med Wkly"},{"key":"1571_CR109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/09513590500231627","volume":"21","author":"M Yilmaz","year":"2005","unstructured":"Yilmaz M, Karakoc A, Toruner FB, Cakir N, Tiras B, Ayvaz G et al (2005) The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 21:154\u2013160","journal-title":"Gynecol Endocrinol"},{"key":"1571_CR110","first-page":"915","volume":"1771","author":"V Zoete","year":"2007","unstructured":"Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferator activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochem Biophys Acta 1771:915\u2013925","journal-title":"Biochem Biophys Acta"},{"key":"1571_CR111","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4161\/derm.1.3.8368","volume":"1","author":"CC Zouboulis","year":"2009","unstructured":"Zouboulis CC (2009) Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 1:188\u2013192","journal-title":"Dermatoendocrinol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-015-1571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-015-1571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-015-1571-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T16:56:13Z","timestamp":1691686573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-015-1571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,19]]},"references-count":111,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s00403-015-1571-1","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,19]]}}}